Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20

Benzinga · 3d ago
Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and raises the price target from $16 to $20.